These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 6878255)

  • 21. [A study of blood rifampin concentration in smoking and non-smoking healthy individuals and in patients with tuberculosis].
    Xie ZY
    Zhonghua Jie He He Hu Xi Za Zhi; 1989 Feb; 12(1):3-5, 60. PubMed ID: 2736668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clearance of theophylline is increased during the initial period of tuberculosis treatment.
    Ahn HC; Lee YC
    Int J Tuberc Lung Dis; 2003 Jun; 7(6):587-91. PubMed ID: 12797703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased nonrenal clearance of cimetidine during antituberculous therapy.
    Keller E; Schollmeyer P; Brandenstein U; Hoppe-Seyler G
    Int J Clin Pharmacol Ther Toxicol; 1984 Jun; 22(6):307-11. PubMed ID: 6746154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy].
    Kawai S
    Nihon Naibunpi Gakkai Zasshi; 1985 Mar; 61(3):145-61. PubMed ID: 4018307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of rifampin administration on the disposition of fexofenadine.
    Hamman MA; Bruce MA; Haehner-Daniels BD; Hall SD
    Clin Pharmacol Ther; 2001 Mar; 69(3):114-21. PubMed ID: 11240975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of plasma lipid on pharmacokinetics of ciclosporin and its relationship with plasma prednisolone level in renal transplant patients.
    Sugioka N; Kokuhu T; Okamoto M; Yoshimura N; Ito Y; Shibata N; Takada K
    J Pharm Pharmacol; 2006 Sep; 58(9):1193-200. PubMed ID: 16945177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and protein binding of prednisolone after oral and intravenous administration.
    Bergrem H; Grøttum P; Rugstad HE
    Eur J Clin Pharmacol; 1983; 24(3):415-9. PubMed ID: 6861855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of d-tubocurarine in patients with thermal injury.
    Martyn JA; Matteo RS; Greenblatt DJ; Lebowitz PW; Savarese JJ
    Anesth Analg; 1982 Mar; 61(3):241-6. PubMed ID: 7199837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories.
    Lintz W; Barth H; Osterloh G; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 Sep; 48(9):889-99. PubMed ID: 9793614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement.
    Wedge SR; Laohavinij S; Taylor GA; Boddy A; Calvert AH; Newell DR
    Clin Cancer Res; 1995 Dec; 1(12):1479-86. PubMed ID: 9815947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide.
    Park JY; Kim KA; Park PW; Park CW; Shin JG
    Clin Pharmacol Ther; 2003 Oct; 74(4):334-40. PubMed ID: 14534520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis.
    Langdon G; Wilkins JJ; Smith PJ; McIlleron H
    Int J Tuberc Lung Dis; 2004 Jul; 8(7):862-7. PubMed ID: 15260278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rifampicin markedly decreases plasma concentration and hypnotic effect of brotizolam.
    Ujiie Y; Fukasawa T; Yasui-Furukori N; Suzuki A; Tateishi T; Otani K
    Ther Drug Monit; 2006 Jun; 28(3):299-302. PubMed ID: 16778710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.
    Nijland HM; Ruslami R; Suroto AJ; Burger DM; Alisjahbana B; van Crevel R; Aarnoutse RE
    Clin Infect Dis; 2007 Oct; 45(8):1001-7. PubMed ID: 17879915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversible metabolism and pharmacokinetics: application to prednisone-prednisolone.
    Wagner JG; DiSanto AR; Gillespie WR; Albert KS
    Res Commun Chem Pathol Pharmacol; 1981 Jun; 32(3):387-405. PubMed ID: 7268190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of uremia on pharmacokinetics and protein binding of prednisolone.
    Bergrem H
    Acta Med Scand; 1983; 213(5):333-7. PubMed ID: 6880855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacokinetics of rifampicin].
    Kohno H
    Nihon Kyobu Shikkan Gakkai Zasshi; 1987 Jan; 25(1):32-7. PubMed ID: 3599578
    [No Abstract]   [Full Text] [Related]  

  • 38. Dose-dependent pharmacokinetics of 1-(2-deoxy-beta-D- ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridine.
    Khalili P; Naimi E; Sun WY; Knaus EE; Wiebe LI
    Biopharm Drug Dispos; 2003 Dec; 24(9):385-95. PubMed ID: 14689467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin.
    Lee KH; Shin JG; Chong WS; Kim S; Lee JS; Jang IJ; Shin SG
    Eur J Clin Pharmacol; 1993; 45(3):287-9. PubMed ID: 8276057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rifampicin induced non-responsiveness to steroids in bronchial asthma.
    Jain NK; Madan A; Jhamaria JP; Sharma TN; Mathur DK; Singh DP
    Indian J Chest Dis Allied Sci; 1989; 31(4):271-4. PubMed ID: 2638668
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.